Loading stock data…
$140.35+2.98 (+2.17%)
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
GRAIL, Inc. in the Healthcare sector is trading at $140.35 with a market capitalization of $3.4B. Wall Street consensus targets $131.30 (10 analysts), implying a -6.4% move over the next 12 months. The stock is currently 16% below its 52-week high of $166.47, remaining 86.1% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.69M↑ | $40.78M↓ | $43.60M↑ | $36.19M↑ | $35.54M |
| Gross Profit | -$12.57M↑ | -$14.31M↓ | -$11.14M↑ | -$13.73M↑ | -$17.77M |
| Operating Income | -$148.36M↓ | -$135.76M↓ | -$124.41M↑ | -$125.29M↑ | -$130.85M |
| Net Income | -$110.25M↓ | -$93.19M↑ | -$99.18M↓ | -$88.98M↑ | -$113.98M |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...